DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC
DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC
DJ ImmunoCellular Files 8K - Director, Officer or Compensation Filing >IMUC
DJ免疫細胞檔案8K-董事、官員或薪酬檔案>IMUC
ImmunoCellular Therapeutics Ltd. (IMUC) filed a Form 8K - Director, Officer or Compensation Filing - with the U.S Securities and Exchange Commission on October 10, 2018.
免疫細胞治療有限公司(IMUC)於2018年10月10日向美國證券交易委員會(U.S.Securities and Exchange Commission)提交了8K表格-董事、官員或薪酬申請。
In connection with the Company's intention to delist its Common Stock and Listed Common Stock Warrants, on October 10, 2018, Dr. Anthony Gringeri notified the Company that he resigned from the Board and as President and Chief Executive Officer of the Company, effective as of October 15, 2018. On the same date, David Fractor and Dr. Steven Swanson each notified the Company of his resignation as Chief Financial Officer and Senior Vice President, as applicable, in each case as of October 15, 2018.
關於本公司擬將其普通股及上市普通股認股權證摘牌的意向，Anthony Gringeri博士於2018年10月10日通知本公司，他已辭去董事會職務及本公司總裁兼行政總裁一職，自2018年10月15日起生效。同一天，David Fracter和Steven Swanson博士分別通知公司他辭去首席財務官和高級副總裁一職(視情況而定)，分別自2018年10月15日起生效。
This Current Report on Form 8-K contains certain forward-looking statements, including statements regarding the Company's intentions and current expectations concerning, among other things, statements regarding the Company's ability to delist its Common Stock and Listed Common Stock Warrants from the NYSE American and deregister its Common Stock and Listed Common Stock Warrants under the Exchange Act, the continuation of Dr. Gringeri, Mr. Fractor and Dr. Swanson as consultants to the Company and the Company's ability to enter into and complete any strategic sale of its assets. Forward-looking statements are not guarantees of future performance and are subject to a number of risks and uncertainties, including the availability of resources to continue to develop the Company's product candidates and the uncertain timing of completion and success of clinical trials. Additional risks and uncertainties are described under the heading "Risk Factors" in the Company's quarterly report on Form 10-Q for the period ended June 30, 2018 and subsequent filings with the SEC. Except as required by law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
這份8-K表格的當前報告包含某些前瞻性陳述，包括有關公司意圖和當前預期的陳述，這些陳述包括但不限於有關公司根據交易法從紐約證券交易所美國交易所退市其普通股和上市普通股認股權證並取消其普通股和上市普通股認股權證註冊的能力、格林格里博士、弗雷泰爾先生和斯旺森博士繼續擔任公司顧問的陳述，以及公司進行和完成其資產的任何戰略性出售的能力的陳述。前瞻性陳述不是對未來業績的保證，會受到許多風險和不確定因素的影響，包括繼續開發該公司候選產品的資源的可用性，以及臨牀試驗完成和成功的不確定時間。其他風險和不確定因素在公司截至2018年6月30日的10-Q表格季度報告和隨後提交給證券交易委員會的文件中的“風險因素”標題下進行了描述。除非法律另有要求，否則公司沒有義務因新信息、未來事件或其他原因而更新或修改任何前瞻性陳述。
The full text of this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/d638594d8k.htm
本證券交易委員會文件全文可在以下網址查閲：http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/d638594d8k.htm
Any exhibits and associated documents for this SEC filing can be retrieved at: http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/0001193125-18-299252-index.htm
本證券交易委員會備案文件的任何證物和相關文件均可在以下網址檢索：http://www.sec.gov/Archives/edgar/data/822411/000119312518299252/0001193125-18-299252-index.htm
Public companies must file a Form 8-K, or current report, with the SEC generally within four days of any event that could materially affect a company's financial position or the value of its shares.
上市公司通常必須在任何可能對公司財務狀況或股票價值產生重大影響的事件發生後四天內向證券交易委員會提交一份8-K表格或當前報告。
(END) Dow Jones Newswires
(完)道瓊通訊社
October 15, 2018 16:35 ET (20:35 GMT)
2018年10月15日美國東部時間16：35(格林尼治標準時間20：35)
Copyright (c) 2018 Dow Jones & Company, Inc.
版權所有(C)2018年道瓊斯公司
譯文內容由第三人軟體翻譯。